MA63885B1 - Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer - Google Patents
Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancerInfo
- Publication number
- MA63885B1 MA63885B1 MA63885A MA63885A MA63885B1 MA 63885 B1 MA63885 B1 MA 63885B1 MA 63885 A MA63885 A MA 63885A MA 63885 A MA63885 A MA 63885A MA 63885 B1 MA63885 B1 MA 63885B1
- Authority
- MA
- Morocco
- Prior art keywords
- pi3k
- methods
- inhibit
- compounds
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231156P | 2021-08-09 | 2021-08-09 | |
| PCT/US2022/039674 WO2023018636A1 (en) | 2021-08-09 | 2022-08-08 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA63885A1 MA63885A1 (fr) | 2024-09-30 |
| MA63885B1 true MA63885B1 (fr) | 2025-01-31 |
Family
ID=83188497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA63885A MA63885B1 (fr) | 2021-08-09 | 2022-08-08 | Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20240343728A1 (enExample) |
| EP (1) | EP4363414A1 (enExample) |
| JP (1) | JP2024533975A (enExample) |
| KR (1) | KR20240051953A (enExample) |
| CN (1) | CN118159534A (enExample) |
| AU (1) | AU2022325819A1 (enExample) |
| CA (1) | CA3227902A1 (enExample) |
| CL (1) | CL2024000327A1 (enExample) |
| CO (1) | CO2024000448A2 (enExample) |
| CR (1) | CR20240045A (enExample) |
| DO (1) | DOP2024000019A (enExample) |
| EC (1) | ECSP24008488A (enExample) |
| GE (1) | GEAP202416449A (enExample) |
| IL (1) | IL310588A (enExample) |
| JO (1) | JOP20240020A1 (enExample) |
| MA (1) | MA63885B1 (enExample) |
| MX (1) | MX2024000708A (enExample) |
| PE (1) | PE20240652A1 (enExample) |
| UA (1) | UA130857C2 (enExample) |
| WO (1) | WO2023018636A1 (enExample) |
| ZA (1) | ZA202401094B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025538147A (ja) | 2022-11-02 | 2025-11-26 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化 |
| WO2024233256A1 (en) | 2023-05-05 | 2024-11-14 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
| WO2025036439A1 (en) * | 2023-08-16 | 2025-02-20 | Laekna Pharmaceutical Ningbo Co., Ltd. | Multicyclic compounds and their use as pi3k alpha inhibitors |
| IL330261A (en) * | 2023-12-27 | 2026-08-01 | Genesis Molecular Ai Inc | Cancer treatment methods |
| WO2025201503A1 (en) * | 2024-03-28 | 2025-10-02 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2026060099A1 (en) * | 2024-09-12 | 2026-03-19 | Kymathera, Inc. | Selective pi3k inhibitors |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010108074A2 (en) * | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| WO2011035855A1 (de) * | 2009-09-28 | 2011-03-31 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate zur hemmung von pi3-kinasen |
| WO2017001645A1 (en) * | 2015-07-02 | 2017-01-05 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| WO2021001431A1 (en) * | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0515025D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| WO2009001089A1 (en) * | 2007-06-26 | 2008-12-31 | Ucb Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
| US9062055B2 (en) * | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| EA201692557A1 (ru) * | 2014-07-04 | 2017-05-31 | Люпин Лимитед | Хинолизиноновые производные в качестве ингибиторов pi3k |
| WO2017221272A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of idelalisib |
-
2022
- 2022-08-08 MA MA63885A patent/MA63885B1/fr unknown
- 2022-08-08 CN CN202280062281.6A patent/CN118159534A/zh active Pending
- 2022-08-08 CR CR20240045A patent/CR20240045A/es unknown
- 2022-08-08 UA UAA202400583A patent/UA130857C2/uk unknown
- 2022-08-08 GE GEAP202416449A patent/GEAP202416449A/en unknown
- 2022-08-08 EP EP22764505.8A patent/EP4363414A1/en active Pending
- 2022-08-08 KR KR1020247007455A patent/KR20240051953A/ko active Pending
- 2022-08-08 US US18/293,823 patent/US20240343728A1/en active Pending
- 2022-08-08 JP JP2024506896A patent/JP2024533975A/ja active Pending
- 2022-08-08 AU AU2022325819A patent/AU2022325819A1/en active Pending
- 2022-08-08 MX MX2024000708A patent/MX2024000708A/es unknown
- 2022-08-08 CA CA3227902A patent/CA3227902A1/en active Pending
- 2022-08-08 IL IL310588A patent/IL310588A/en unknown
- 2022-08-08 WO PCT/US2022/039674 patent/WO2023018636A1/en not_active Ceased
- 2022-08-08 PE PE2024000156A patent/PE20240652A1/es unknown
-
2024
- 2024-01-18 CO CONC2024/0000448A patent/CO2024000448A2/es unknown
- 2024-02-01 EC ECSENADI20248488A patent/ECSP24008488A/es unknown
- 2024-02-01 JO JOJO/P/2024/0020A patent/JOP20240020A1/ar unknown
- 2024-02-02 CL CL2024000327A patent/CL2024000327A1/es unknown
- 2024-02-02 ZA ZA2024/01094A patent/ZA202401094B/en unknown
- 2024-02-02 DO DO2024000019A patent/DOP2024000019A/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010108074A2 (en) * | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| WO2011035855A1 (de) * | 2009-09-28 | 2011-03-31 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate zur hemmung von pi3-kinasen |
| WO2017001645A1 (en) * | 2015-07-02 | 2017-01-05 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| WO2021001431A1 (en) * | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024000327A1 (es) | 2024-08-09 |
| ZA202401094B (en) | 2025-05-28 |
| IL310588A (en) | 2024-04-01 |
| ECSP24008488A (es) | 2024-05-31 |
| EP4363414A1 (en) | 2024-05-08 |
| CN118159534A (zh) | 2024-06-07 |
| JOP20240020A1 (ar) | 2024-02-01 |
| UA130857C2 (uk) | 2026-05-27 |
| CA3227902A1 (en) | 2023-02-16 |
| JP2024533975A (ja) | 2024-09-18 |
| CR20240045A (es) | 2024-02-20 |
| KR20240051953A (ko) | 2024-04-22 |
| PE20240652A1 (es) | 2024-04-04 |
| WO2023018636A1 (en) | 2023-02-16 |
| CO2024000448A2 (es) | 2024-02-15 |
| DOP2024000019A (es) | 2024-03-15 |
| AU2022325819A1 (en) | 2024-02-29 |
| GEAP202416449A (en) | 2024-04-25 |
| MA63885A1 (fr) | 2024-09-30 |
| US20240343728A1 (en) | 2024-10-17 |
| MX2024000708A (es) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202311329B (en) | Urea derivatives which can be used to treat cancer | |
| JOP20240020A1 (ar) | مركبات تثبط الصورة المتماثلة ألفا لـ pi3k وطرق لعلاج السرطان | |
| JOP20220131A1 (ar) | مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة | |
| MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
| MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
| EP2091328A4 (en) | SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| WO2023107723A3 (en) | Cyclic compounds and their use for the treatment of neurological disorders | |
| EA201001821A1 (ru) | Производные триазола, полезные для лечения заболеваний | |
| SA523451700B1 (ar) | (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان | |
| MA44948A1 (fr) | Inhibiteurs de bace 1 | |
| MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MX2024007062A (es) | Compuestos heterociclicos como inhibidores de dyrk1a. | |
| MA41494B1 (fr) | Composés benzoxaborole substitués en position 4 et utilisations associées | |
| JOP20220281A1 (ar) | مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها | |
| MX2025004073A (es) | Métodos para tratar el cáncer | |
| GEAP202416416A (en) | Urea derivatives which can be used to treat cancer | |
| EP2073635A4 (en) | MACROCYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| UY39819A (es) | Métodos para tratar el cáncer | |
| PH12023551898A1 (en) | Cyclic oxaphosphinane compounds and analogues thereof for treating fibrotic diseases | |
| AR126147A1 (es) | Derivados de urea para tratar el cáncer | |
| MA34327B1 (fr) | Dérivés de flufénoxine pour le traitement et la prévention des pathologies amyloïdes | |
| MX2025007377A (es) | Inhibidores de jak2 |